{
  "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
  "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 39,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "The slide highlights the clinical need for new therapies due to resistance mutations (G2032R) and CNS involvement.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/10",
  "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
  "deckJsonHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json",
  "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.51,
        "x": 0.076,
        "y": 0.895
      },
      "kind": "source-note",
      "text": "Sources: Lin et al., J Thorac Oncol 2017; Gainor et al, JCO Precision Oncol 2017; Ou and Zhu Lung Cancer 2019; Patil et al, JTO 2018",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6be118ce-03b7-4608-9fb3-b0feff8d27f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.495,
        "w": 0.864,
        "x": 0.068,
        "y": 0.305
      },
      "kind": "table",
      "text": "Line of Therapy, Sub-population, Incidence (US), CNS Disease, Standard of Care (2022)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50019560-79b6-4e32-9a51-fdd8593612f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.685,
        "x": 0.076,
        "y": 0.185
      },
      "kind": "title",
      "text": "Emerging resistance mutations and increasing CNS involvement limit utility of approved therapies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8058882-dd0e-4513-b648-85decc413fe5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.415,
        "x": 0.076,
        "y": 0.115
      },
      "kind": "title",
      "text": "ROS1-positive NSCLC Market Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74de6568-ec9e-4f67-82e6-12bb1dea4deb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "c2e9a912-1259-437b-9377-64b47b091262",
      "evidence": "ROS1-positive NSCLC Market Overview",
      "confidence": 0.5
    },
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "4b69bf1d-4070-4662-b161-e96c9c0e96e7",
      "evidence": "Line of Therapy, Sub-population, Incidence (US), CNS Disease, Standard of Care (2022)",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "74e5d306-f6f2-40eb-8437-b8542677fbbe",
      "evidence": "Segments market by line of therapy and mutation status",
      "confidence": 0.7
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 10,
      "beatId": "4cedff80-36c0-4bbc-a462-ced06248d8ee",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Sizing",
      "beatSlug": null,
      "evidence": "The market for ROS1-positive NSCLC is sized.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "781a9db6-60df-4e5f-9ef7-9eb3f3b812ae",
      "evidence": "The limitations of current treatments are discussed.",
      "position": 0,
      "objective": "What are the consequences of not addressing kinase resistance?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}